Clinical Trials
60 trialsMK-3475-G21
Merck Sharp & Dohme LLC
OP-NEU-101
Onchilles Pharma Inc
ACTengine
Immatics US, Inc.
ARTACUS
Replimune, Inc.
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
SELECT-CAR-NK
Essen Biotech
EBNK-ST-001
Essen Biotech
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Study of GV20-0251 in Participants With Solid Tumor Malignancies
GV20 Therapeutics
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Anaveon AG
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Novartis
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
ABILITY-1
Medicenna Therapeutics, Inc.
START-001
Marengo Therapeutics, Inc.
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
BioAtla, Inc.
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Krystal Biotech, Inc.
ENHANCE
Xynomic Pharmaceuticals, Inc.
Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.
Rabin Medical Center
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
GV20 Therapeutics
INJECTABL-1
Immunophotonics, Inc.
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Iovance Biotherapeutics, Inc.
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Vector Vitale LLC
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
ENB Therapeutics, Inc
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
National Cancer Institute (NCI)
MEL60
University of Virginia
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Apexigen America, Inc.
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
4D pharma plc
PIVOT IO 020
Bristol-Myers Squibb
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Study of ADI-PEG 20 in Patients With Advanced Melanoma
Ludwig Institute for Cancer Research
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
Akeso
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Genocea Biosciences, Inc.
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Effector Therapeutics
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene